| Name | Title | Contact Details |
|---|
Verily`s mission is to make the world`s health data useful so that people enjoy longer and healthier lives. The company was launched in 2015 and is a subsidiary of Alphabet. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. The company partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale.
Gallus Biopharmaceuticals is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eTherapi is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company`s inaugural offering includes a portfolio of intelligent Virtual Agents specially trained to streamline phone-based administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III